Why a peptide calculator for tirzepatide doesn't apply to licensed Mounjaro

What the trial evidence actually tells us about tirzepatide dosing

NICE's appraisal of tirzepatide, published as TA1026 in December 2024, draws on a structured clinical programme in which dose was titrated systematically from 2.5 mg upward at roughly four-week intervals. The SURMOUNT-1 trial, which enrolled 2,539 adults with obesity, produced average body-weight reductions of around 20–21% at the 15 mg maintenance dose over 72 weeks. Those results came from a protocol in which every participant's dose was managed by clinicians following a fixed schedule, not from individual peptide calculations or improvised reconstitution.

That clinical discipline is one reason the results were so consistent. The KwikPen format used in licensed Mounjaro reflects the same logic: each pen delivers a precise, pre-set volume of a verified concentration, manufactured under pharmaceutical-grade conditions. There is no calculation to do on the patient's side because Eli Lilly has already done it.

A question our prescribers hear most weeks is whether starting at a lower dose than 2.5 mg would reduce side effects further. The short answer is that 2.5 mg is itself a tolerability dose (its job is to ease the body into treatment rather than produce immediate weight loss) and going lower has no licensed evidence base. The prescriber decides whether to proceed on schedule or to extend a dose level; that call belongs with the clinician, not a tirzepatide calculator online.

Why peptide calculators exist, and why they're not relevant here

Online tirzepatide peptide calculators were built for a different context entirely: research settings where tirzepatide powder is weighed and dissolved in bacteriostatic water to create an injectable solution of a chosen concentration. Tools like a tirzepatide mixing calculator or a BAC water calculator serve that workflow.

In the UK, that pathway is not a legitimate route to weight management treatment. Tirzepatide is a Prescription-Only Medicine under the Human Medicines Regulations 2012. Selling or supplying it without a valid prescription is unlawful, and raw peptide products (often described as "research use only") sit firmly outside the licensed supply chain. The MHRA has warned publicly about counterfeit and illegally traded weight-loss products; enforcement in 2025 included the seizure of approximately 20 million doses with a street value of around £45 million, and a raid on an unlicensed manufacturing site producing counterfeit tirzepatide pens.

Dosing errors are the most immediate clinical risk. Unlike a pre-filled pen where the dose is mechanically fixed, a reconstituted solution requires accurate weighing, correct volume calculations, and sterile technique, none of which most people undertaking a weight-loss programme will have access to at home. A small arithmetic slip can produce a concentration many times higher than intended.

How dose is actually managed on licensed Mounjaro

The Mounjaro KwikPen is designed so the patient does not interact with the dose at all. Each pen contains four weekly doses at a single fixed strength. You inject once a week, at one of three sites (abdomen, thigh or upper arm, rotated), and the pen does the rest. Detailed administration guidance is in the Patient Information Leaflet that comes with every pen, and on the NHS tirzepatide medicines page.

Dose decisions (when to move from 2.5 mg to 5 mg, whether to stay at a lower dose longer because of GI side effects, whether to pause) belong to your prescriber. At nume, a GPhC-registered Independent Prescriber personally reviews every consultation and every repeat order. No algorithm makes those calls. If a dose increase is requested, our clinical team checks for supporting evidence before approving it.

For anyone exploring what tirzepatide treatment might look like in practice, the tirzepatide overview page covers the licensed mechanism, the titration schedule, eligibility criteria and what to expect in the first weeks. Cost context (including how private pricing has changed since Eli Lilly revised its UK list prices in September 2025) is covered on the Mounjaro cost page.

What to do if you have questions about your dose

If you are already on licensed tirzepatide and wondering whether your current dose is right, the answer starts with your prescriber, not a search engine and not a calculator tool. Common concerns include whether the starting dose is "doing anything" (it takes time; the therapeutic effect builds across the titration schedule), whether a missed injection changes the plan (the Patient Information Leaflet sets out the guidance; your prescriber can advise for your specific situation), and whether side effects at one level mean you should move more slowly.

The frequently asked questions page addresses many of these practical points. For anything requiring a clinical view, our support team can connect you with the prescribing team seven days a week. That aftercare is included as standard, no separate fee, no subscription to maintain access to it.

If you haven't yet started treatment and are weighing up whether licensed tirzepatide through a regulated service is the right path, speaking to our prescribers is the first step. The consultation is free and reviewed the same day.